Preliminary evaluation of the human relevance of respiratory tumors observed in rodents exposed to naphthalene

Regulatory Toxicology and Pharmacology

Volumn 62, Issue 3, 2012, Pages 433-440

  Piccirillo, Vincent J ^a   Bird, Michael G ^b   Lewis, R Jeffrey ^b   Bover, W James ^b  

^a VJP Consulting Inc   (United States)

^b EXXONMOBIL UPSTREAM RESEARCH COMPANY   (United States)

Author keywords

Carcinogenicity; Human relevance framework; Mode of action; Naphthalene; Nasal cancer

Indexed keywords

CYTOCHROME P450; CYTOCHROME P450 2A13; CYTOCHROME P450 2F; EPOXIDE HYDROLASE; GLUTATHIONE; NAPHTHALENE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BIOASSAY; CARCINOGENESIS; CHEMICAL ANALYSIS; CHEMICAL STRUCTURE; CONTROLLED STUDY; ENVIRONMENTAL EXPOSURE; ENZYME METABOLISM; HYDROLYSIS; LYMPHOCYTE; MOUSE; NONHUMAN; OXIDATION; OXIDATION REDUCTION REACTION; OXIDATIVE STRESS; POINT MUTATION; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN DEPLETION; RAT; RESPIRATORY SYSTEM; RESPIRATORY TRACT DISEASE; SPECIES DIFFERENCE; STATISTICAL SIGNIFICANCE; STEREOCHEMISTRY;

ANIMALS; ARYL HYDROCARBON HYDROXYLASES; DRUG EVALUATION; HUMANS; LUNG NEOPLASMS; MICE; NAPHTHALENES; RATS; SPECIES SPECIFICITY;

MUS; RATTUS; RODENTIA;

EID: 84857664607     PISSN: 02732300     EISSN: 10960295     Source Type: Journal    
DOI: 10.1016/j.yrtph.2012.01.008     Document Type: Article

References (49)

1. Baldwin R.M., et al. Comparison of pulmonary/nasal CYP2F expression levels in rodents and rhesus macaque. Journal of Pharmacology and Experimental Therapeutics 2004, 309:127-136.
2. Bogen K.T. An adjustment factor for mode of action uncertainty with dual-mode carcinogens: the case of naphthalene-induced nasal tumors in rats. Risk Analysis 2008, 28:1033-1051.
3. Bogen K.T., et al. Naphthalene metabolism in relation to target tissue anatomy, physiology, cytotoxicity and tumorigenic mechanism of action. Regulatory Toxicology and Pharmacology 2008, 51:27-36.
4. Boobis A.R., et al. IPCS framework for analyzing the relevance of a cancer mode of action for humans. Critical Reviews in Toxicology 2006, 36:781-792.
5. Brusick D.J., et al. Possible genotoxic modes of action for naphthalene. Regulatory Toxicology and Pharmacology 2008, 51:43-50.
6. Brusick D.J. Critical assessment of the genetic toxicity of naphthalene. Regulatory Toxicology and Pharmacology 2008, 51:37-42.
7. Buckpitt A., et al. Naphthalene-induced respiratory tract toxicity: metabolic mechanisms of toxicity. Drug Metabolism Reviews 2002, 34:791-820.
8. Buckpitt, A., et al., 2011. Kinetics of naphthalene metabolism in target and nontarget tissues of rodents and in nasal and airways microsomes from the Rhesus monkey. (Unpublished report to the Naphthalene Research Committee).
9. Buckpitt A.R., Warren D.L. Evidence for hepatoic formation, export and covalent binding of reactive naphthalene metabolites in extrahepatic tissues in vivo. Journal of Pharmacology and Experimental Therapeutics 1983, 225:8-16.
10. Cho T.M., et al. In vitro metabolism of naphthalene by human liver microsomal cytochrome P450 enzymes. Drug Metabolism and Disposition: The Biological Fate of Chemicals 2006, 34:176-183.
11. Cohen S., et al. Evaluating the human relevance of chemically induced animal tumors. Toxicological Sciences 2004, 78:181-186.
12. Cohen S., et al. The human relevance of information on carcinogenic mode of action: overview. Critical Reviews in Toxicology 2003, 33:581-589.
13. Dodd D.E., et al. Nasal olfactory epithelial lesions in F344 and SD rats following 1- and 5-day inhalation exposure to naphthalene vapor. International Journal of Toxicology 2010, 29:175-184.
14. Dodd D.E., et al. Nasal epithelial lesions in F344 rats following a 90-day inhalation exposure to naphthalene. Inhalation Toxicology 2012, 24:70-79.
15. Feng P.C., et al. Metabolism of alachlor by rat and mouse liver and nasal turbinate tissues. Drug Metabolism and Disposition: The Biological Fate of Chemicals 1990, 18:373-377.
16. Green T., et al. Acetochlor-induced rat nasal tumors: further studies on the mode of action and relevance to humans. Regulatory Toxicology and Pharmacology 2000, 32:127-133.
17. Green T., et al. The influence of co-exposure to dimethyldithiocarbamate on butadiene metabolism. Chemico-Biological Interactions 2001, 135-136:585-598.
18. Heydens W.F., et al. An evaluation of the carcinogenic potential of the herbicide alachlor to man. Human and Experimental Toxicology 1999, 18:363-391.
19. Phenacetin (Group 2A) and analgesic mixtures containing phenacetin (Group 1). Overall evaluation of carcinogenicity: an updating of IARC Monographs. IARC, Lyon Supplement 1987, 7:310-312. International Agency for Research on Cancer (IARC).
20. Monographs on the Evaluation of the Carcinogenic Risk of Chemicals to Humans, Volume 82: Some Traditional Herbal Medicines, Some Mycotoxins, Naphthalene and Styrene 2002, International Agency for Research on Cancer (IARC), World Health Organization, Lyon, France.
21. Isaka H., et al. Tumors of the Sprauge-Dawley rats induced by long-term feeding of phenacetin. Gann 1979, 70:29-36.
22. Jefferies P.R., et al. Dialkylquinonimines validated as in vivo metabolites of alachlor, acetochlor and metolachlor herbicides in rats. Chemical Research in Toxicology 1998, 11:353-359.
23. Jeffrey A.M., et al. Nasal cytotoxic and carcinogenic activities of systemically distributed organic chemicals. Toxicologic Pathology 2006, 34:827-852.
24. Lambert G.R., et al. Quantitative analysis of alachlor protein adducts by gas chromatography-mass spectrometry. Analytical Biochemistry 1999, 268:289-296.
25. Lewis D.F.V., et al. Molecular modeling of CYP2F substrates: comparison of naphthalene metabolism by human, rat and mouse CYP2F subfamily enzymes. Drug Metabolism and Drug Interactions 2009, 20:229-257.
26. Lewis R.J. Naphthalene animal carcinogenicity and human relevancy: overview of industries with naphthalene-containing streams. Regulatory Toxicology and Pharmacology 2012, 62:131-137.
27. Li A.A., et al. Metabolism of alachlor by rat and monkey liver and nasal turbinate tissue. Drug Metabolism and Disposition: The Biological Fate of Chemicals 1992, 20:616-618.
28. Magee B., et al. Screening-level population risk assessment of nasal tumors in the US due to naphthalene exposure. Regulatory Toxicology and Pharmacology 2010, 57:168-180.
29. Martignoni M., et al. Species differences between mouse, rat, dog, monkey and human CYP-mediated drug metabolism, inhibition and induction. Expert Opinion on Drug Metabolism & Toxicology 2006, 2:875-894.
30. Meek M.E. Recent developments in frameworks to consider human relevance of hypothesized modes of action for tumours in animals. Environmental and Molecular Mutagenesis 2008, 49:110-116.
31. Meek M.E., et al. A framework for human relevance of information on carcinogenic modes of action. Critical Reviews in Toxicology 2003, 33:591-653.
32. Meng F., et al. P53 codon 271 CGT to CAT mutant fraction does not increase in nasal respiratory and olfactory epithelia of rats exposed to inhaled naphthalene. Mutation Research/Genetic Toxicology and Environmental Mutagenesis 2011, 721:199-205.
33. Morris, J. B., 2011. Personal communications.
34. National Toxicology Program (NTP), 1992. Toxicology and Carcinogenesis Study of Naphthalene in B6C3F1 Mice (Inhalation Studies). Technical Report Series No. 410.
35. National Toxicology Program (NTP), 2000. Toxicology and Carcinogenesis Study of Naphthalene in F344/N Rats (Inhalation Studies). Technical Report Series No. 500.
36. Palackal N.T., et al. Metabolic activation of polycyclic aromatic hydrocarbon trans-dihydrodiols by ubiquitously expressed aldehyde reductase (AKR1A1). Chemico-Biological Interactions 2001, 130-132:815-834.
37. Penning T.M., et al. Dihydrodiol dehydrogenases and polycyclic aromatic hydrocarbon activation: generation of reactive and redox active o-quinones. Chemical Research in Toxicology 1998, 12:1-18.
38. Phimister A.J., et al. Glutathione depletion is a major determinant of inhaled naphthalene respiratory toxicity and naphthalene metabolism in mice. Toxicological Sciences 2004, 82:268-278.
39. Recio, L., 2011. Personal communications.
40. Recio, L., et al., 2011. Dose-response assessment of naphthalene-induced genotoxicity and glutathione detoxication in human TK6 lymphoblasts. Toxicological Sciences, in press.
41. Sridhar G.R., et al. Amino acid adducts of PAH o-quinones: model studies with naphthalene-1,2-dione. Tetrahedron Letters 2001, 57:407-412.
42. Sugiyama K., et al. Aldose reductase catalyses the oxidation of naphthalene-1,2-dihydrodiol for the formation of ortho-naphthoquinone. Drug Metabolism and Disposition: The Biological Fate of Chemicals 1999, 27:60.
43. USEPA, 2001. The grouping of a series of chloroacetanilide pesticies based on a common mechanism of toxicity. Health Effects Division. June 7, 2001.
44. USEPA, 2004a. External Review Draft: Toxicological Review of Naphthalene (CAS No. 91-20-3). In Support of Summary Information on the Integrated Risk Information System (IRIS). NCEA-S-1701, August, 1998, reviewed June, 2004.
45. USEPA, 2004b. Summary information on the Integrated Risk Information System (IRIS) for naphthalene (CAS No. 91-20-3), June 2004.
46. van Bladeren P.J., et al. Stereoselectivity of cytochrome P-450c in the formation of naphthalene and anthracene 1,2-oxides. Journal of Biological Chemistry 1984, 259:8966-8973.
47. Van Winkle, L., 2010. Personal communications.
48. Warren D.L., et al. Evidence for cytochrome P450 mediated metabolism in the bronchiolar damage by naphthalene. Chemico-Biological Interactions 1982, 40:287-303.
49. Wetmore B.A., et al. Evidence for site-specific bioactivation of alachlor in the olfactory mucosa of the Long-Evans rat. Toxicological Sciences 1999, 49:202-212.